1,1'-(Piperazine-1,4-diyl)bis(3-bromopropan-1-one)
| Title | Journal |
|---|---|
| Benign familial polycythaemia in a young male. | Hematology reports 20120102 |
| Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20111010 |
| Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. | Thrombosis 20110101 |
| The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. | Thrombosis 20110101 |
| Emerging treatments for essential thrombocythemia. | Journal of blood medicine 20110101 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Polycythemia vera. | Internal and emergency medicine 20101001 |
| Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox. | Journal of inflammation (London, England) 20100101 |
| Essential thrombocythemia: past and present. | Internal and emergency medicine 20091001 |
| Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. | Journal of medicinal chemistry 20081113 |
| [Confluent indurated facial nodules and pustules in a 55-year-old man]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20080901 |
| A case of bromoderma and bromism. | The British journal of dermatology 20080201 |
| Pipobroman gets regulatory approval outside Germany. | Deutsches Arzteblatt international 20080101 |
| Practical approach to treating essential thrombocythaemia: case studies. | European journal of haematology. Supplementum 20071001 |
| A review of the therapeutic agents used in the management of polycythaemia vera. | Hematological oncology 20070601 |
| The treatment of polycythaemia vera: an update in the JAK2 era. | Internal and emergency medicine 20070301 |
| Essential thrombocythemia. | Orphanet journal of rare diseases 20070101 |
| [Multiples squamous cell carcinomas during treatment with pipobroman]. | Annales de dermatologie et de venereologie 20070101 |
| Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. | Seminars in thrombosis and hemostasis 20060601 |
| Del(5q) and MLL amplification in homogeneously staining region in acute myeloblastic leukemia: a recurrent cytogenetic association. | Annals of hematology 20060401 |
| Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. | Blood 20050401 |
| Cytogenetic response to pipobroman in Philadelphia-positive chronic myeloid leukemia with thrombocythemic onset. | Annals of hematology 20050201 |
| Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug. | Haematologica 20041101 |
| Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. | Annals of hematology 20040801 |
| Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. | British journal of haematology 20031101 |
| Polycythemia vera. | Hematology/oncology clinics of North America 20031001 |
| Pharmacotherapy of essential thrombocythaemia: economic considerations. | Expert opinion on pharmacotherapy 20030901 |
| Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. | Leukemia & lymphoma 20030901 |
| Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. | Current hematology reports 20030501 |
| Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. | Haematologica 20030101 |
| Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea. | Acta haematologica 20030101 |
| Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. | The hematology journal : the official journal of the European Haematology Association 20030101 |
| [Polycythemia vera]. | La Revue du praticien 20021015 |
| Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. | Leukemia 20021001 |
| What is the standard treatment in essential thrombocythemia. | International journal of hematology 20020801 |
| Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. | British journal of haematology 20020301 |
| Bone marrow aplasia after pipobroman: an immune-mediated mechanism? | British journal of haematology 20011201 |
| [Multiple skin and mouth squamous cell carcinomas related to long-term treatment with hydroxyurea]. | Annales de dermatologie et de venereologie 20010901 |
| [Hydroxyurea--is it a harmless drug in Vaquez disease?]]. | Pathologie-biologie 20010301 |
| Management of patients with essential thrombocythemia: current concepts and perspectives. | Pathologie-biologie 20010301 |
| Current treatment practice for essential thrombocythaemia in adults. | Expert opinion on pharmacotherapy 20010301 |
| [Synthesis and anti-tumor activities of 1,4-bis[3-(amino-dithiocarboxy)propionyl] piperazine derivatives]. | Yao xue xue bao = Acta pharmaceutica Sinica 20010301 |
| Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera. | Leukemia & lymphoma 19990501 |